A Randomized, Open-label, Multi-center, Phase I, Crossover Study to Assess the Relative Bioavailability of 2 Oral Formulations of TKI258 (CSF Capsule vs. FMI Tablet), and the Effect of Food on the Bioavailability of TKI258, in Patients With Advanced Solid Tumors.
Phase of Trial: Phase I
Latest Information Update: 01 Apr 2015
At a glance
- Drugs Dovitinib (Primary)
- Indications Solid tumours
- Focus Pharmacokinetics
- 07 Nov 2013 Planned End Date changed from 1 Jul 2013 to 1 Feb 2015 as reported by ClinicalTrials.gov.
- 07 Jun 2013 Status changed from active, no longer recruiting to completed, based on the 49th Annual Meeting of the American Society of Clinical Oncology abstract.
- 04 Jun 2013 Results presented at the 49th Annual Meeting of the American Society of Clinical Oncology.